Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. Its product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
Company profile
Ticker
FPRX
Exchange
Website
CEO
Thomas Civik
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FIVE PRIME THERAPEUTICS INC
SEC CIK
Corporate docs
IRS number
260038620
FPRX stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
26 Apr 21
EFFECT
Notice of effectiveness
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
Transcripts
FPRX
Earnings call transcript
2020 Q3
3 Nov 20
FPRX
Earnings call transcript
2020 Q3
3 Nov 20
FPRX
Earnings call transcript
2020 Q2
9 Aug 20
FPRX
Earnings call transcript
2020 Q1
9 May 20
FPRX
Earnings call transcript
2019 Q4
27 Feb 20
FPRX
Earnings call transcript
2019 Q3
6 Nov 19
FPRX
Earnings call transcript
2019 Q2
9 Aug 19
FPRX
Earnings call transcript
2019 Q1
9 May 19
FPRX
Earnings call transcript
2018 Q4
26 Feb 19
FPRX
Earnings call transcript
2018 Q3
6 Nov 18
Latest ownership filings
SC 13G/A
Rock Springs Capital Management LP
15 Feb 22
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
17 May 21
4
Francis Willard Sarena
19 Apr 21
4
David V Smith
19 Apr 21
4
Helen Louise Collins
19 Apr 21
4
David White
19 Apr 21
4
WILLIAM R RINGO
19 Apr 21
4
FRANKLIN M BERGER
19 Apr 21
4
Kapil Dhingra
19 Apr 21
4
Peder Jensen
19 Apr 21
Financial summary
Quarter (USD) | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 70.97 mm | 70.97 mm | 70.97 mm | 70.97 mm | 70.97 mm | 70.97 mm |
Cash burn (monthly) | (no burn) | (no burn) | 7.33 mm | 7.74 mm | 4.42 mm | 5.39 mm |
Cash used (since last report) | n/a | n/a | 291.64 mm | 308.02 mm | 176.00 mm | 214.44 mm |
Cash remaining | n/a | n/a | -220.68 mm | -237.06 mm | -105.03 mm | -143.47 mm |
Runway (months of cash) | n/a | n/a | -30.1 | -30.6 | -23.8 | -26.6 |
Institutional ownership, Q1 2023
13.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 240.87 mm |
Total shares | 6.34 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 6.34 mm | $240.87 mm |